Efficacy of triamcinolone acetonide combined with conbercept in patients with wet age-related macular degeneration who have poor response to ranibizumab treatment

Liu Ya-wen; Zhang Li-you; Wu Wen-wen; Lu Lu

doi:10.3969/j.issn.1672-8157.2025.01.021

Abstract：Objective To investigate the efficacy of triamcinolone conbercept with compaucil in the treatment of wet age-related macular degeneration(wAMD)with poor response to ranibizumab.Methods A total of 188 patients with wAMD who exhibited a poor response to ranibizumab treatment admitted to Cangzhou Eye Hospital from August 2023 to August 2024 were retrospectively en-rolled in this study.They were divided into the control group and study group by random number table method,with 94 in each group.The patients in the control group received treatment with conbercept while those in the study group received treatment with triamcino-lone acetonide in combination with conbercept.All the patients in both groups were treated for 3 months.Comparisons were conducted between the two groups regarding best-corrected visual acuity(BCVA),intraocular pressure(IOP),central macular thickness(CMT),fundus damage and recurrence rate before and after treatment.Results The IOP of the control group and study group after treatment((16.01±2.33)mm Hg(1 mm Hg≈0.133 kPa)and(16.08±2.35)mm Hg,respectively)was higher than that before treatment((15.55±1.45)mm Hg and(15.53±1.46)mm Hg,respectively),but there was no statistical difference between the two groups(t=0.205,P>0.05).The BCVA of of the control group and study group after treatment((15.36±2.22)and(17.65±3.35),respectively)was high-er than that before treatment((10.56±3.11)and(10.59±3.10),respectively),and it was significantly higher in the study group than in the control(t=5.525,P<0.05).After treatment,the CMT in the control group and study group((356.20±56.14)μm and(271.69±62.25)μm,respectively)was lower than that before treatment((436.65±96.36)μm and(434.64±95.34)μm,respectively),and it was significantly lower in the study group than in the control(t=9.774,P<0.05).The areas of bleeding,damage and leakage in the con-trol group and study group after treatment were(0.89±0.55)mm2,(0.50±0.41)mm2,(0.96±0.47)mm2,(0.63±0.17)mm2,(2.88±0.68)mm2,and(2.10±0.17)mm2,respectively,which were lower than those of(1.25±0.58)mm2,(1.23±0.57)mm2,(1.98±0.36)mm2,(1.94±0.33)mm2,(3.87±1.03)mm2,and(3.84±1.00)mm2 before treatment,and they were remarkably lower in the study group than in the control(t=5.512,6.401,10.789,P<0.05).The recurrence rate was 1.06%in the study group and it was lower than that of 19.15%in the control,(χ2=16.921,P=0.000).Conclusion The combination of conbercept with triamcinolone acetonide in invalids with wAMD who have poor response to ranibizumab has clear clinical efficacy since it can effectively reduce vascular dys-plasia,alleviate clinical symptoms,promote visual recovery and results in a low recurrence rate.